Dato' Foong Chee Meng


Chong Siew Mun
Tan Chien Li
Liew Sue Yin
Leong Wai Lun
Khor Wei Min


Datin Lai Yoke Leng
Liang Soo Chee
Choo Kang Wei


Chuar Pei Yin
Khor Shu Han
Yap Kha Ying
Vivian Chew Li Voon
Chia Keng Teah
Foo Jia Yi
Tay Xiao Bing
Abigail Cheong

LIEW SUE YIN
Partner

d +603 6419 0839
f +603 6419 0823
e sueyin@foongpartners.com

Qualifications
University of Wales, Cardiff, U.K. (LL.B, Hons)

Admissions
Malaysia Bar

Sue Yin graduated with LL.B (Hons) from University of Wales, Cardiff, UK and was admitted to practise in 2002.

Sue Yin began legal practice in S F Chan & Co. where she advised on various civil litigation, family law, commercial and land matters. Prior to joining Foong & Partners in 2005, she practised with Deol & Co.

Sue Yin's client profile includes public listed companies, foreign companies, small and medium-sized enterprises, family-owned businesses and high net worth individuals.

She has experience in advising on various corporate, commercial, property, loans, moneylending and capital markets matters. She has been involved, amongst other things, in share and business acquisitions, joint ventures, initial public offerings in Malaysia and in other juridictions and other fund-raising exercises such as rights issues and bonus issues. She has also advised foreign direct investors on the various aspects of commencing and conducting business operations in Malaysia.

Some of the mergers and acquisitions transactions Sue Yin has advised and acted in recent years include the disposal by Pacific & Orient Berhad of its 49% interest in Pacific & Orient Insurance Co. Berhad for a cash consideration of RM270 million and the acquisition of certain properties in Malaysia for Tune Hotels Sdn Bhd.

In respect of capital markets work, Sue Yin advised and acted for Dolphin International Berhad for its offering and listing on the Main Market of Bursa Malaysia, which raised gross proceeds of RM31.28 million. She also advised and acted for Hyphens Pharma International Pte. Ltd. (a Singapore-based speciality pharmaceutical and consumer healthcare group), as Malaysian counsel in relation to its public offering and listing on the Catalist Board of Singapore Stock Exchange, which raised gross proceeds of S$13.5 million.